Podcasts about microba

In the previous episode we heard how some rationally-designed therapies work on almost any cancer with the right molecular signature. Tumour-agnostic medications could be godsend for patients with rare cancers which have classically been overlooked by drug developers, and those with advanced cancers of unknown origin. 15,000 such patients have undergone comprehensive genome profiling of their tumours through the organisation, Omico. In this podcast, Omico's founder explains that while the majority have received recommendations about matched therapies, clinical trials are typically the only way to enable access. Professor David Thomas discusses why Australia's Health Technology Assessment process appears to be so conservative and how the market price of next-generation oncotherapies might be brought down by changes across the local ecosystem. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico)  Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes  ‘Multicolor' and ‘Pulse Voyage' by Chill Cole. ‘Impulsing', ‘the City of Hope' ‘Over Again', and ‘Going Undercover' by Borrtex provided courtesy of FreeMusicArchive. Image by Guido Mieth licenced through Getty Images.  Editorial feedback kindly provided by RACP physicians Simeon Wong, Stephen Bacchi. Thanks also to Kym Bramich and Arnika Martus on staff with Omico and RACP respectively.  Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

The genomic understanding of cancer has transformed a tissue-based classification model that had been dominant for 150 years or more. The last three decades have seen highly targeted therapies developed at blistering pace, and unprecedented improvements in patient outcomes. To date, these advances have been focused on more common cancers. The financing model for drug development means that rare cancers get overlooked, given the small pool of potential buyers relative to the costs and risks of investment. However, the molecular targets characterised in more common cancers are often found in cancers of a different histotype. As such, precision therapies will sometimes have tissue-agnostic efficacy and offer a lifeline for patients with neglected diseases or cancers of unknown origin. Professor David Thomas has founded an NGO called Omico to enable such patients to undergo profiling for hundreds of potential molecular targets. In this interview he explains the rationale for the most promising pan cancer therapies, and in the next episode we discuss changes to the regulatory and funding model required to sustain this screening program. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico) Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘the Orchard' by Jakob Ahlbom, ‘Dusty Electronics' and ‘Pulse Voyage' by Chill Cole, ‘Tam' by LJ Kruzer, ‘See you soon' and ‘Going Undercover' by Borrtex. Image by filo licenced through Getty Images. Editorial feedback was kindly provided by RACP physicians Nichola Ball, Stephen Bacchi, Aafreen Khalid, Simeon Wong, Maansi Arora and Aidan Tan.Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

Microba Life Sciences Ltd (ASX:MAP) CEO Dr Luke Reid sits down with Proactive's Tylah Tully live from the ASX Small and Mid Cap Conference in September 2024. Microba Life Sciences believes in comprehensive and precise measurement of the human gut microbiome to drive innovation in medical care. Through its analysis and discovery platforms, the company identifies novel microbiome-derived therapeutics and new diagnostic tools to advance medicine. The growing team is built on a foundation of scientific and technical excellence and a drive to discover ever-deeper insights into the relationships between gut microorganisms and health. The company works with international partners who share its passion and scientific rigour to fast-track these new advances. #ProactiveInvestors #MicrobaLifeSciences #ASX #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Send us a Text Message.In this week's episode, Jess is joined by Natural Super Kids Naturopath Sarah Worboys to dive into the topic of microbiome testing and address questions from Natural Super Kids members. Sarah has been a frequent guest on the podcast and brings a wealth of knowledge and experience to this discussion.In last week's episode, Jess welcomed Dr. Brad Leech, a PhD-qualified Clinical Nutritionist and Herbalist and Lead Clinical Educator at Co-Biome by Microba, to the podcast to explore gut microbiome testing. If you haven't listened to this episode yet, be sure to check it out here.Throughout this episode, Sarah and Jess share:How microbiome testing has evolved;Research on cohabitation and the gut microbiome;Testing the gut microbiome in children;When Sarah considers microbiome testing; A case study where Sarah utilised microbiome testing and gained valuable insights;Questions surrounding microbiome testing from Natural Super Kids members and their recommendations;Microbiome testing options and pricing; Testing for food intolerances and leaky gut.This episode explored the latest research and practical applications of microbiome testing, particularly for children. We hope this episode has answered your questions and provided a deeper understanding of how microbiome testing can be a powerful tool for optimising health. Episode Links:Listen to Episode 33 'Meet our new Naturopath, Sarab Worboys' here Listen to Episode 66 'Common poop signs in children with Naturopath Sarah Worboys' here Listen to Episode 123 'A case study on resolving enlarged adenoids and tonsils in children naturally with Sarah Worboys' hereListen to Episode 139 'Navigating perimenopause with Natural Super Kids Naturopath, Sarah Worboys' here Listen to Episode 157 'How naturopathy can support sleep issues in children' with Sarah Worboys hereListen to Episode 158 'Melatonin to support children's sleep' with Sarah Worboys here Check out the Co-Biome website here Book a consultation with Sarah here

Send us a Text Message.In this weeks episode, Jess is joined by Dr. Brad Leech, PhD-qualified Clinical Nutritionist and Herbalist Dr. Brad Leech, to discuss gut microbiome testing. Dr. Brad Leech specialises in  complex gastrointestinal disorders and chronic autoimmune conditions, offering personalised care to his patients through functional nutrition, integrative medicine, and holistic wellness. As the Lead Clinical Educator at Co-Biome by Microba, Dr. Brad Leech uses his expertise in gastrointestinal healthcare to translate the latest gut microbiome research into practical clinical applications.In this episode, Jess and Brad discuss:Dr. Brach Leech's journey to specialising in gut and autoimmune conditions;Key markers and bacteria analysed in gut microbiome tests and their impact on symptoms;How comprehensive microbiome testing is identifying potential issues;How  gut microbiome test results can explain children's symptoms;Symptoms or conditions that strongly indicate the need for gut testing;The accuracy of gut microbiome tests and Dr. Brad Leech's testing recommendations;The best course of action once you have identified any issues;Dr. Brad Leech's number one intervention for children's microbiome health. Dr. Leech's extensive knowledge and practical approach offers valuable insights into understanding and addressing gut health issues in children. This episode will give listeners a clearer understanding of the markers and bacteria analysed in gut microbiome tests, the accuracy of these tests, and actionable steps to improve gut health. Episode Links:Check out Dr. Brad Leech's Website Here  Follow Dr. Brad Leech on Instagram

Our understanding of infectious disease and pathology stems from the 19th century with Robert Koch pioneering research. Dr Koch help to shaped modern microbiology and medicine when he identified the causative agents for anthrax and tuberculosis. Since that time, the number of infectious microorganisms that we know of that cause illness and diseases has increased exponentially. Thanks to modern day techniques, laboratories can test for these agents directly or indirectly and get an answer often within hours. As such, microbiology is on the verge of a new era. Instead of the principle of one test: one micro-organism, we are moving into the realm where one test can detect hundreds of potential pathogens and antimicrobial resistance genes in a single stool sample. The new test is called Metapanel. This includes 175 gene targets using metagenomics (shotgun gene sequencing) and is able to detect bacteria, viruses, helminths, protozoa, fungi, microsporidia. This information is collated and reported by a pathologist and advice given as to what is the implications of the result. The test is ideally suited for patients with chronic diarrhoea, inflammatory bowel disease and/or inflammatory bowel syndrome. This is the story of advanced faeces testing and Metapanel ** Please note: General Practitioners in Australia, will be able to claim CPD points after listening to this episode. Full details and registration, coming shortly. Our special guest: Dr Michael Wehrhahn is the Director of Molecular Biology and Infectious serology at Douglass Hanly Moir Pathology. Michael has a Master in Public Health, is an Infectious Disease Specialist as well as a Microbiologist and Adjunct Senior Lecturer at the University of Notre Dame. Dr Wehrhahn is actively involved in research on clinical and laboratory aspects of a range of microorganisms and is a reviewer for a number of journals. Michael has been involved in researching and validating the new Metapanel available through Sonic in conjunction with Microba. This Medical Life podcast is available on all podcasting services and Spotify. Help support us at https://www.patreon.com/ThisMedicalLifeSee omnystudio.com/listener for privacy information.

In this episode of The SIBO Doctor Podcast, Dr. Nirala Jacobi discusses: -  The Gut Microbiome's Role. The gut microbiome's influence on health and disease is significant, with modern lifestyles negatively impacting its state. -  Microbiome Diversity. A diverse microbiome, akin to a healthy ecosystem, is crucial for preventing overgrowth of harmful bacteria and maintaining overall health. - Metabolites. Bacterial genes in the microbiome produce metabolites that can indicate health status and influence mood and energy levels. Restore the Microbiome - New online course: Dr Jacobi's strategies to rewild the microbiome, emphasizing the importance of diversity and the production of beneficial metabolites. Resources mentioned in this podcast: Learn more about the new Restore Your Microbiome course on The SIBO Doctor. Order your Microbiome Insight test from Microba.

In July 2022, Defence launched the 'Safeguarding Australia through Biotechnology Response and Engagement' (SABRE) Alliance, to bring together biotech capabilities from Australia's universities, research institutes, SMEs and manufacturers to connect them with the needs of the Defence and national security sectors. MTPConnect has played a role in establishing the SABRE Alliance and in March 2023, the ‘Advancing the SABRE Alliance' workshop was held in Canberra, as part of the ‘Science Meets Parliament' program. Our podcast host Caroline Duell was at the event to find out about the initiative and how the sector can get involved. We hear from SABRE Alliance Co- Chairs, Dr Peter Shoubridge (DSTG) and Professor Mark Hutchinson (STA), who explain the origins and purpose of the SABRE Alliance. SABRE Committee members Sue MacLeman, Professor Emily Hilder (DSTG), Dr Leigh Farrell (DMTC) and Major Ricky Schmidt talk about the importance of industry, science and researchers coming together to solve Defence's most pressing needs. We also hear from industry and science representatives, UQ's Professor Trent Munro from Microba, Professor Jia-Yee Lee from the University of Melbourne, Paul Davies from Abbott and Dr Andy Shepherd from CSIRO. 

Microba is an Australian biotech company using microbiome science to improve human health, with the involvement of some real heavyhitters behind it, including Gardasil creator Professor Ian Frazer AC.Sean Aylmer talks to Microba CEO Dr Luke Reid about the path to commercialising medical innovation, and why Brisbane has become such a hub for this technology.The Brisbane Economic Development Agency is a supporter of this podcast.Find out more: https://fearandgreed.com.auSee omnystudio.com/listener for privacy information.

Continue on to learn about the remaining stocks, Microba Life Sciences (ASX:MAP) and Monash IVF (ASX:MVF), as well as what to expect from these companies in 2023. In this video, Dr. Tara discusses:- (0:34) Impacts of Ferring's FDA approval on Microba- (5:30) Drivers behind Microba's increase in revenue - (7:12) What 2023 looks like for Monash IVF- (8:39) Monash IVF's rating- (11:45) Monash IVF's impact from legal actionNote: This interview was filmed on 7 February 2023.

Vivimos en un mundo de bacterias. Fueron los primeros seres vivos que surgieron en el planeta hace 3600 millones de años, en las fumarolas volcánicas del fondo de los océanos o en los charcos calientes. Están en todos los ambientes, desde el borde de los volcanes hasta las plataformas heladas de los polos. Y también en nuestro cuerpo: tenemos 100 billones de células microbianas, 10 veces más que células humanas. El humano promedio traga un billón de bacterias cada día. Y solo en nuestra boca habitan más de 600 especies. Ellas nos defienden, educan el sistema inmune, nos ayudan a procesar los alimentos e incluso modifican emociones y comportamientos. Solo algunas causan enfermedades y, aunque tenemos antibióticos, las bacterias más dañinas se hacen cada vez más resistentes. ¿La infección común se volverá mortal? Neumonía, tuberculosis, septicemia, gonorrea, infecciones urinarias o enfermedades de transmisión alimentaria, entre otras, son cada vez más difíciles —y a veces imposibles— de tratar. En los últimos años se han atribuido directamente a las bacterias resistentes alrededor de 23.000 muertes anuales en estados unidos y más de 25.000 en la unión europea. El abuso de los antibióticos médicos y veterinarios ha hecho que esté en riesgo su eficacia. ¿Cómo contener esta resistencia? ¿Cómo puede la vacunación protegernos de enfermedades? Oye en este podcast —disponible en Spotify, iVoox o tu plataforma favorita— una conversación en la que abordamos estas y otras preguntas con Natalia Jiménez Quiceno, M.Sc. y Ph.D. en ciencias básicas biomédicas, coordinadora de la línea de epidemiología molecular bacteriana, grupo Microba, escuela de microbiología UdeA. Nos acompaña también Gustavo Roncancio, médico internista, especialista en enfermedades infecciosas, clínica Cardiovid, profesor de la universidad pontificia bolivariana e investigador grupo Microba de la Universidad de Antioquia. Apoya nuestra labor educativa: VaxThera y Sura.

February is Gut Health Month. This month I am focusing on your gut health after weight loss surgery. There is some literature around gut health and bariatric surgery, however more research is needed. In this episode, I speak about a subgroup of nutrients called flavonoids. Flavio-what? You ask? Bear with me. These groups of nutrients are so potent in their ability to be anti inflammatory, anti-cancer and anti-aging. Sounds good right?Weight loss surgery significantly changes your gut health and bacteria population. I dive deep into the use of flavonoids as a way to change this gut bacteria to support your metabolism. Here is the Literature Referenced for this month's content: Dietary flavan-3-ols intake and metabolic syndrome risk in Korean adults Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits The Thinking on FlavonoidsA review of FlavonoidsFlavonoids: an overviewThe effects of bariatric surgery on gut microbiota in patients with obesity: a review of the literature; PMID: 30705797 Longitudinal changes of microbiome composition and microbial metabolomics after surgical weight loss in individuals with obesityRoux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation What are Flavonoids?Microbiome dynamics in obesityDr Kaylyn Tousignant 2020; Microba; Microbial diversity: The key to improving gut healthLet's chat: Work with me 1:1 by learning about my coaching: https://simpleandeasynutrition.com/apply.html Website: https://www.thebariatriccollective.com.au/ Instagram: @thebariatriccollective Facebook: https://www.facebook.com/thebariatriccollective Email: suraya@thebariatriccollective.com.au Free Downloads: Causes of Weight Regain Graphic Download a Free Three Day Meal Plan with Recipes DISCLAIMER The advice provided in the podcast is general in nature and is not intended to constitute or substitute for dietetics, nutrition, professional or medical advice. You should not rely on the information presented here as medical advice. It is important to consult a medical professional for personalised medical or dietetic advice for your specific circumstances.

US stocks slid at the closing bell of the midweek session as investors shifted focus back to corporate earnings reports and away from dovish comments by Fed Chair Jerome Powell about the future of US cash rate hikes amid slowing economic growth.Lumen Technologies tanked more than 20% after reporting a fourth-quarter loss of US$3.1bn and provided guidance for the year that fell well short of Wall St expectations. Disney on the other hand reported results after the closing bell that topped analysts' expectations including a loss of US$1.05bn which was less than Wall Street had predicted, earnings per share of 99 cps, well above the expected 78 cents per share, revenue of US$23.61bn and total Disney+ subscriptions of 161.1m which declined by around 2.4million on the back of a recent price increase. The Dow Jones fell 0.61%, the S&P500 tumbled 1.11%, and the Nasdaq lost 1.68% on Wednesday.Over in Europe markets rallied on Wednesday following dovish comments from Fed chair Jerome Powell as well as investors digesting mixed corporate earnings reports. Jewellery company Pandora rose 12% on upbeat earnings results including quarterly sales hitting 9.9 billion Danish Crowns or $1.43 billion dollars, and annual sales around 26bn in 2022. The UK's FTSE100 hit an intraday record high before paring back gains to close the day up 0.3%. In Germany, the DAX added 0.6% while the French CAC fell 0.18% on Wednesday. What to watch today:Taking a look at commodities today, crude oil is trading 1.57% higher at US$78.35/barrel, gold is flat at US$1874/ounce and iron ore is trading down 0.8% at US$124.50/tonne.The Aussie dollar is buying US$0.69, 90.97 Japanese yen, 57.56 British pence, and NZ$1.10.Ahead of the local trading session the market is expected to open 0.42% lower following the sell-off on Wall St overnight.On the economic data front today, there is no local economic data out today however investors will be awaiting the release of the RBA statement on Monetary Policy out tomorrow. Trading Ideas:Bell Potter has increased the price target on Microba Life Sciences (ASX:MAP) from $0.40 to $0.60 following the execution of an exclusive distribution agreement with Luminary Health Centres to distribute a microbiome test powered by Microba's testing technology, to consumers in the US. Bell Potter sees the deal has locked in revenue for the next 12-months and is the driver of the price target increase for Microba.Trading Central has identified a bullish signal on Race Oncology (ASX:RAC) following the formation of a pattern over a period of 36-days which is roughly the same amount of time the share price may rise from the close of $2.05 to the range of $2.15-$2.19 according to standard principles of technical analysis.

February is Gut Health Month. This month I am focusing on your gut health after weight loss surgery. There is some literature around gut health and bariatric surgery, however more research is needed. In this episode, I explain the basics of your gut. There is over 95 trillion species of bacteria in the gut from the mouth all the way through to the anus. Gut diversity has a strong influence on health and risk of disease. Struggling with obesity may mean that you have had a historically low diversity of your gut bacteria.Weight loss surgery is a strong catalyst for change in the gut bacteria. The effects may not be sustained, which further research is needed. However, I question whether this has a role in weight regain after bariatric surgery. I also provide you with three practical strategies that you can implement today to support your gut health. Here is the Literature Referenced for this month's content: The effects of bariatric surgery on gut microbiota in patients with obesity: a review of the literature; PMID: 30705797; https://pubmed.ncbi.nlm.nih.gov/30705797/ Longitudinal changes of microbiome composition and microbial metabolomics after surgical weight loss in individuals with obesity: https://doi.org/10.1016/j.soard.2019.05.038 Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation; https://pubmed.ncbi.nlm.nih.gov/26244932/ What are Flavonoids? https://www.livescience.com/52524-flavonoids.html#:~:text=Flavonoids%20are%20a%20diverse%20group,with%20more%20than%206%2C000%20types. Microbiome dynamics in obesity; https://pubmed.ncbi.nlm.nih.gov/30467161/ Dr Kaylyn Tousignant 2020; Microba; Microbial diversity: The key to improving gut health; https://insight.microba.com/blog/microbial-diversity-the-key-to-improving-gut-health/ Stomach pH before vs. after different bariatric surgery procedures: Clinical implicationsLet's chat: Work with me 1:1 by learning about my coaching: https://simpleandeasynutrition.com/apply.html Website: https://www.thebariatriccollective.com.au/ Instagram: @thebariatriccollective Facebook: https://www.facebook.com/thebariatriccollective Email: suraya@thebariatriccollective.com.au Free Downloads: Causes of Weight Regain Graphic Download a Free Three Day Meal Plan with Recipes DISCLAIMER The advice provided in the podcast is general in nature and is not intended to constitute or substitute for dietetics, nutrition, professional or medical advice. You should not rely on the information presented here as medical advice. It is important to consult a medical professional for personalised medical or dietetic advice for your specific circumstances.

#266 Dr. Brad Leech is an internationally recognised Integrative Medicine Practitioner with over 10 years of clinical experience. He has taught and developed subjects at leading academic institutions in Integrative Gastroenterology, Naturopathic Medicine, Nutritional and Dietetic Medicine, and Public Health Research. Dr. Brad Leech is the Clinical Science Lead at Microba, where his expertise in integrative gastrointestinal healthcare enables him to translate the latest science on the gut microbiome into practical clinical applications. In addition to his research and working with patients, Brad offers practitioner support through his mentoring program Brad's Brainiacs.    In this episode we cover A summary of different testing methods used to identify the microbiome and pathogens The latest research on antimicrobials and the microbiome How we can use this research in clinical practice How clinicians can safely and effectively use antimicrobials in clinical practice Herbs that Brad would potentially avoid using altogether as the Risk is not worth the benefit Herbs that nourish the microbiome And so much more

#264 Dr. Paula Smith-Brown is the Clinical Science Lead at Microba and an Adjunct Lecturer at Centre for Microbiome Research at The Queensland University of Technology. She is a PhD qualified Accredited Practising Dietitian who combines her experience as a microbiome researcher and healthcare professional to translate the latest science on the gut microbiome into practical clinical application.  In this episode we cover How microbial dysbiosis plays a role in IBS If the microbiome is different in those with IBS The impact a low FODMAP diet has on the microbiome FODMAP food reintroduction. How to tackle this if a patient has been on a low fodmap diet for some time If we can predict a response to a low FODMAP diet based on microbiome Strategies and interventions And so much more  

Microba Life Sciences CEO Luke Reid speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022. Microba is advancing healthcare through precision microbiome science. The company believes comprehensive and precise measurement of the human gut microbiome is required to drive innovation in medical care. Its therapeutic discovery is generating multiple potent therapeutic candidates to address unmet clinical needs for multiple chronic diseases. #Microba #asx #proactiveaustralia #microbiome

Brad Leech is an internationally recognised Clinical Nutritionist and Ayurvedic Herbalist. After entering the integrative medicine profession in 2008, Brad has taught and developed subjects at leading academic institutions in Integrative Gastroenterology, Naturopathic Medicine, Nutritional and Dietetic Medicine and Public Health Research. As Clinical Science Lead in integrated and functional medicine at Microba, his expertise in integrative gastrointestinal healthcare enables him to translate the latest science on the gut microbiome into practical clinical application.  Brad has just finished his PhD at the Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney. His research involved developing the IP Guideline, an evidence-based clinical practice guideline for the management of increased intestinal permeability. His previous research has focused on autoimmune disease management, health outcomes associated with food-based probiotics and integrative healthcare management.

#250 Dr. Paula Smith-Brown is the Clinical Science Lead at Microba and an Adjunct Lecturer at the Centre for Microbiome Research at The Queensland University of Technology. She is a PhD-qualified Accredited Practising Dietitian who combines her experience as a microbiome researcher and healthcare professional to translate the latest science on the gut microbiome into practical clinical application. Dr. Paula Smith-Brown has a specialist interest in infant and child nutrition and allergies and intolerances in all ages and is the founder of the ABC nutrition clinic.   In this episode we cover The prevalence of allergies in children Why children in Australia are getting more early-onset eczema and allergies The importance of the microbiome in immune development What families who can not breastfeed can do to support a child's health Why not all topical nappy cream preparations are great  Why timely introduction of complementary foods is important Strategies to prevent allergy And so much more

#245 Dr. Paula Smith-Brown is the Clinical Science Lead at Microba and an Adjunct Lecturer at Centre for Microbiome Research at The Queensland University of Technology. She is a PhD qualified Accredited Practising Dietitian who combines her experience as a microbiome researcher and healthcare professional to translate the latest science on the gut microbiome into practical clinical application.  In this episode we cover How microbial dysbiosis plays a role in IBS If the microbiome is different in those with IBS The impact a low FODMAP diet has on the microbiome FODMAP food reintroduction. How to tackle this if a patient has been on a low fodmap diet for some time If we can predict a response to a low FODMAP diet based on microbiome Strategies and interventions And so much more  

#218 Christine is a Nutritionist and Registered Nurse and works as a Clinical Application Specialist at Microba. Christine has a passion for chronic disease prevention and further understanding the association between the microbiome and disease. She has worked in a number of settings ranging from clinical through to public health nutrition and is a board director on Nutrition Australia's National Board. In this episode we cover What serotonin is commonly known for It's other, fascinating not so known properties How serotonin is produced in the gut How serotonin affects gut motility Serotonin's influence on pathogens and vice versa How to increase serotonin production What negatively impacts serotonin production

As part of a documentary series we are producing we talked to Dr Alena Pribyl from Microba in Brisbane, Australia, about the gut microbiome and specifically what this has to do with mental health. She was so interesting we just had to get her on the show for all to hear. Sorry the audio isn't the best, we had some bandwidth issues on the day - but hopefully it's clear enough for you to catch all she presents. This is a very important topic and we can't wait to show you the documentary! For more about Dr Pribyl and the documentary go to the landing page for this episode here. For our latest book giveaways check out our recent content here https://www.thescienceofpsychotherapy.com/latest-content/ Please leave a review! (Reviews are fabulously important to us! On your podcast player you should find an option to review at the bottom of the main page for the podcast - after the list of available episodes) - Here's a link for iTunes. Thanks for listening! Support this show by subscribing to The Science of Psychotherapy Please leave an honest review on iTunes and please subscribe to our show.  You can also find our podcast at: The Science of Psychotherapy Podcast Homepage If you want more great science of Psychotherapy please visit our website thescienceofpsychotherapy.com - and get the app! Details in the footer of our site.

On todays show we have Gut Health Specialist Linda Conder who I interviewed a few episodes ago which I recommend to listen to first to get a better understanding of what gut health is, how it effects our mood, immune system, our performance and preventing disease. So I recently had a gut health test from a company called Microba if you're interested but Linda takes us through all the species and bacteria in my gut which either have a positive or negative effect on my health. There is some great information in this episode for you to improve your health and overall well-being so I hope you enjoy it, my inbox is always open so for any questions send them my way or in the show notes you can get in contact with Linda through her website or social media and please remember to like and subscribe to the podcast if you haven't already. Website: https://www.lindaconder.com/health  Email: health@lindaconder.com  Facebook: Linda Conder Nutritional Medicine   Gut Bacteria Test: https://insight.microba.com/learn-more/   Instagram: joelcurtispt

Dr Paula Smith-Brown is a PhD-qualified Accredited Practising Dietitian and Clinical Science Lead at Microba, an Australian company and a world leader in the analysis of the gut microbiome.  For more information on Microba, microbiome testing with professional courses and support check out https://insight.microba.com/ For more information on the online international diabetes revolution summit on July 31st, check out https://www.lifestylemedicine.org.au/diabetes-revolution-summit/ If you find this podcast valuable, rating it 5 stars and leaving a review is appreciated. If you would like to provide feedback or request a topic, please Contact Us. Thank you for listening

My Guest today is a qualified nutritional medicine practitioner and now Head of Healthcare Operations and Development for Queensland-based microbiome testing and research company, Microba. Hayley Parcel leads a team of healthcare professionals to drive clinical understanding and implementation of gut microbiome analysis at Microba and today we do a truly fascinating deep dive into what cutting-edge research is telling us about the contents of your large intestine, and the implications for personalised nutrition. You can oder a gut microbiome test directly though Microba here.If you're a health professional that's interested in working with Microba, click here.Here's what we talk about in the podcast:4:38 - Microba company beginnings5:44 - An overview of the gut microbiome 7:56 - Technological advances in gut microbiome analysis10:09 - Your 2-way relationship with your microbiome11:33 - Probiotics vs prebiotics14:58 - Why you can't out-supplement a bad diet21:28 - The microbiome in human health & disease23:04 - The microbiome and mental health27:00 - Insights from fecal transplants29:57 -  Early life influences on your microbiome32:05 - The microbiome and your immune system35:38 - The impacts of different diets44:50 - Shotgun metagenomics technology for microbiome anlaysis47:55 - Microba and health practitioners49:28 - Getting your own microbiome tested51:52 - The future of microbiome research

Christine Stewart is a qualified nutritionist and a Clinical Application Specialist at Microba. As a DNA sequencing company, Microba uses cutting edge technology to provide comprehensive gut health testing and microbiome analysis. In her role with Microba, Christine supports fellow practitioners in best serving their clients and analysing test results. With a passion for gut health and dealing with the root cause, Christine is a perfect example of someone in their dream job. Find the full episode show notes and topics covered here: https://nutritiongradguide.com/podcast/episode-42-christine-stewart Learn more about Microba at https://www.microba.com/. Follow Christine's journey via her instagram @christine_stewart_nutritionist and her website https://www.nutritioning.com.au/.

Bianca Maree is an integrative Dietitian achieving amazing things in the industry! She combines her entrepreneurial spirit with part time work for Microba. When she isn't working for Microba, she's growing her two businesses, one of which focuses on gut health and the other that is all about female empowerment. Bianca takes us behind the scenes and tells us all about how she combines these passions and makes a positive impact on so many people's lives. You can learn more about Bianca by checking out her website https://www.biancamaree.com.au/ and following her instagram accounts @biancamaree_x and @balancedbellas_.

For all the gut science nerds out there like me you are just going to love this episode. Today I interview Dr Alena Pribyl who is the senior scientist and research officer at Microba, the very lab we use at Kultured Wellness to analyse our clients' gut microbiome. Listen in as we discuss the cutting edge science around sequencing and latest insights into the gut microbiome as it relates to mental health, cancer and more.

In today's episode we are sitting down with Bianca Maree, Dietitian and Lead Microbiome Coach for Australian company Microba. In this episode we talk all about gut health, how you can test your gut health with Microba and finally how you can use those results to improve your gut health. I loved talking with Bianca and I really think you will get a lot of value out of our conversation. Enjoy :) WIN! Announced on the first Monday of every month, one lucky winner will receive a Limited Edition ‘Stay Zesty' Glitter Tshirt. Want to win? All you need to do is leave a 5 star rating and review on the apple podcast app. Good luck! Find me: @thezestylifepodcast @britanydovenorhealth The Zesty Life Community www.britanydovenorhealth.com britanydovenor@gmail.com Mentioned: Microba @biancamaree_x https://www.biancamaree.com.au/ 

Our Guest: Dr. Ken McGrath is the Clinical Liaison Manager with Microba. He obtained his PhD in Biochemistry and Molecular Pathology from the University of Queensland, and has a research background in microbial genomics, including human microbiomes and metagenomic analysis. Ken was the manager of a DNA sequencing laboratory 10 years prior to joining Microba, and is a member of several international microbiome research projects, including global pathogen detection and monitoring. Ken is now helping Microba bring the latest gut microbiome technology to healthcare practitioners and educate and inform them of how the information can benefit their patient management. _______________ Topics: The main types of gut testing available The difference between culture based stool testing and DNA based stool testing (+ what the heck it all means) DNA testing further explained + knowing which type of DNA based gut test is best What we get through the GP when requesting basic gut testing and what can and can't that tell us Microbiome sequencing - what it does and doesn't tell us The kinds of conditions, symptoms or presentations that can benefit from comprehensive microbiome testing  How long it takes for our gut to change after implementing dietary and lifestyle changes How often we should get testing be done Loads more! _________   Social & Website Links https://www.microba.com/ https://www.instagram.com/microbaofficial/ https://www.facebook.com/MicrobaOfficial/ https://twitter.com/MicrobaOfficial https://www.linkedin.com/company/microba/  

About Our Guest: Dr Pribyl is the Senior Scientist and Research Officer with biotech company Microba, a leader in the analysis of the gut microbiome. She has expertise in human microbiome research, microbiology, and stress physiology in fish. She also has a passion for science communication to support science-informed decision making. Dr Pribyl received her Ph.D. in Fisheries Science in 2010 from Oregon State University, was a National Research Council Postdoctoral Fellow, and was a CCST Science & Technology Policy Fellow before moving to Australia in 2015 where she started working at the Australian Centre for Ecogenomics at the University of Queensland in the area of the human microbiome. She has presented at many conferences and seminars to science and laymen audiences.   Podcast Topics: What are the characteristics of an “ideal” or healthy gut? What happens to the bacteria when we take Antibiotics? Are antibiotics the only thing that alters our microbiome, or are there other drugs or hormones that have the ability to change the microbiome? Can we recover species lost after Antibiotics? The difference between a probiotic and a prebiotic Probiotics - broad-spectrum or strain-specific? Impact of carbohydrate restriction on the microbiome The best "diet" for a healthy gut Resources & Social Medica Links: https://www.microba.com/ https://www.instagram.com/microbaofficial/ https://www.facebook.com/MicrobaOfficial/ https://twitter.com/MicrobaOfficial https://www.linkedin.com/company/microba/  

In episode 248 of The Real Food Reel we are joined by Senior Scientist and Research Officer with biotech company Microba, Dr Alena Pribyl. In today's episode, we explore microbiome testing technology, how it has evolved over the years and what makes shotgun metagenomic sequencing so remarkable. You will learn how one smear sample can tell you so much about your health, the significance of microbial metabolites, how poor digestive capacity may be explored, markers of inflammation, what it means to have high levels of human DNA identified and so much more. Dr Pribyl is an absolute wealth of knowledge and I hope this episode inspires you to have your microbiome tested and remove the guess work when it come to your health.   Learn more here: Microba: https://www.microba.com Mapping Your Microbiome: https://thenaturalnutritionist.com.au/mapping-your-microbiome/ RFR 237 Mapping Your Gut Microbiome with Kirsty Wirth: http://thewellnesscouch.com/rfr/rfr-237-mapping-your-gut-microbiome-with-kirsty-wirth   Book your consultation with TNN here: bit.ly/tnnonline Click below to download transcript: The post RFR 248: Understanding Your Microbiome with Microba's Dr Alena Pribyl appeared first on The Wellness Couch.

The influence of our guts on our broader, holistic health is more significant than one might think, as Microba senior scientist and research officer Alena Pribyl explains on this week's episode of The Wellness Daily Show. In conversation with host Jerome Doraisamy, Ms Pribyl explains what we mean by gut health and gut microbiome, what to look for in a health microbiome, the dangers of not taking proper care of our guts and what we can do to ensure a healthier approach for our physical, emotional and psychological wellbeing.  

In episode 237 of The Real Food Reel we are joined by Kirsty Wirth from Kultured Wellness to discuss mapping your gut microbiome. We explore the technology we have had access to, to date, and its limitations including culturing, PCR and 16s RNA. We then discuss the newest technology, shot-gun metagenomic sequencing and how this provides much greater functional insight and therefore, clinical relevance. We then dive deeper into Microba's insight report and the importance of microbiome metabolites for optimal digestive, metabolic and nervous system health. Follow Kirsty online: https://www.kulturedwellness.com Facebook: /kulturedwellness Instagram: @kulturedwellness   Submit your questions here: https://thenaturalnutritionist.com.au/contact/ Click below to download transcript: The post RFR 237: Mapping Your Gut Microbiome with Kirsty Wirth appeared first on The Wellness Couch.